13 July 2025 : Clinical Research
Development and Validation of a Predictive Nomogram for Early Postoperative Recurrence in Non-Small Cell Lung Cancer
Zhi Liang ABCDEF 1, Wei Lin ABCD 1, Shipeng Fang BCDF 1, Jianhao Zhang BCDF 1, Jianhui Chen BCDF 1, Feng Yuan A 2*DOI: 10.12659/MSM.948441
Med Sci Monit 2025; 31:e948441
Table 1 Demographic and clinical characteristics of patients.
| Characteristic | Control Group (n=235) | Observation Group (n=51) | Statistics (t/χ2/Z) | P value |
|---|---|---|---|---|
| Age (years) | 66.6±9.1 | 66.1±9.3 | 0.354 | 0.723 |
| Sex (Male) | 151 (64.3%) | 32 (62.7%) | 0.041 | 0.849 |
| Smoking history | 147 (62.6%) | 31 (60.8%) | 0.056 | 0.813 |
| Histological type (adenocarcinoma) | 94 (40.0%) | 20 (39.2%) | 0.011 | 0.917 |
| Histological type (squamous cell carcinoma) | 141 (60.0%) | 31 (60.8%) | – | – |
| Adjuvant chemotherapy (No) | 194 (82.6%) | 44 (86.3%) | 0.416 | 0.519 |
| Adjuvant chemotherapy (Yes) | 41 (17.4%) | 7 (13.7%) | – | – |
| Hypoalbuminemia (No) | 157 (66.8%) | 32 (62.7%) | 0.309 | 0.579 |
| Hypoalbuminemia (Yes) | 78 (33.2%) | 19 (37.3%) | – | – |
| Anemia (No) | 148 (63.0%) | 32 (62.7%) | 0.001 | 0.975 |
| Anemia (Yes) | 87 (37.0%) | 19 (37.3%) | – | – |
| Pleural invasion (No) | 185 (78.7%) | 26 (51.0%) | 16.67 | <0.001 |
| Pleural invasion (Yes) | 50 (21.3%) | 25 (49.0%) | – | – |
| Lymphovascular invasion (No) | 174 (74.0%) | 30 (58.8%) | 4.746 | 0.029 |
| Lymphovascular invasion (Yes) | 61 (26.0%) | 21 (41.2%) | – | – |
| Tumor differentiation (high/moderate) | 181 (77.0%) | 31 (60.8%) | 5.760 | 0.016 |
| Tumor differentiation (Low) | 54 (23.0%) | 20 (39.2%) | – | – |
| T stage (T1) | 163 (69.4%) | 25 (49.0%) | 7.699 | 0.006 |
| T stage (T2/T3) | 72 (30.6%) | 26 (51.0%) | – | – |
| Lymph node metastasis (No) | 195 (83.0%) | 22 (43.1%) | 36.34 | <0.001 |
| Lymph node metastasis (Yes) | 40 (17.0%) | 29 (56.9%) | – | – |
| D-dimer (<0.5 mg/L) | 194 (82.6%) | 33 (64.7%) | 8.152 | 0.004 |
| D-dimer (≥0.5 mg/L) | 41 (17.4%) | 18 (35.3%) | – | – |
| CEA (<5.0 ng/mL) | 191 (81.3%) | 32 (62.7%) | 8.379 | 0.004 |
| CEA (≥5.0 ng/mL) | 44 (18.7%) | 19 (37.3%) | – | – |
| CEA – carcinoembryonic antigen | ||||